Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [815]

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non...

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple...

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum...

Prof Siow-Ming Lee - University College London, London, UK

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in...

Prof Siow-Ming Lee - University College London, London, UK

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

OncoAlert and ecancer weekly round up for August 15th - 21st, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 15th - 21st, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )

More from ecancer